Pharma Mar(OTC) PHMMF

Pharma Mar, S.A. is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing bioactive compounds from marine organisms, primarily for oncology applications. The company operates in key markets including Europe and the United States, with a diverse portfolio targeting various cancer types.

Products and Services

• Yondelis® for soft tissue sarcomas and ovarian cancer
• Aplidin® for multiple myeloma
• Zepzelca® for small cell lung cancer

Growth Outlook

• Recent quarterly revenue of €42.9 million shows strong market demand
• Ongoing Phase II trials for PM14 may expand oncology offerings
• Strategic focus on diagnostics and RNA interference could drive future growth

Financial Highlights

• Trailing twelve months (TTM) revenue of €90.4 million reflects solid performance
• Net income margin of 35.7% indicates strong profitability
• Current ratio of 3.06 suggests robust liquidity position

Pharma Mar, S.A. has established itself as a leader in the biotechnology sector, particularly in oncology. The company's innovative approach to harnessing marine-derived compounds positions it uniquely within the pharmaceutical landscape. Recent financial performance highlights a strong revenue trajectory, with a notable net income margin that underscores effective cost management and operational efficiency. The ongoing development of new therapies and diagnostic tools further enhances the company's growth potential, making it an intriguing option for investors interested in the biotechnology field.